Streetbeat News

Revenues

AMZN

BBY

MS

TGT

WMT

Walmart Inc's CEO Doug McMillon discussed the normalization of hiring post-pandemic and the company's effective staffing across the U.S. Walmart raised its minimum wage to $14, following competitors like Target, Amazon, and Best Buy who set theirs at $15. CFO John David Rainey noted challenges in predicting consumer behavior due to economic pressures and observed unusual spending patterns in late October. Despite this, Walmart's long-term strategy remains unchanged. Thanksgiving weekend saw increased consumer spending due to significant discounts, alleviating some concerns about reduced spending. Walmart shares were up 0.27% in premarket trading.

Portfolio Pulse from Nabaparna Bhattacharya

December 07, 2023 | 1:56 pm

CHWY

SMTC

SVFD

Save Foods (SVFD) shares surged 107% after the company announced the acquisition of majority ownership in Nitrousink Ltd, targeting the US carbon credit market. Chewy (CHWY) shares fell 13% following mixed Q3 results and reduced FY23 net sales guidance. Semtech (SMTC) shares rose 16% after reporting positive Q3 financial results and providing guidance.

Portfolio Pulse from ryanfaloona@benzinga.com

December 07, 2023 | 1:44 pm

WBUY

WEBUY GLOBAL reported an interim H1 2023 revenue of $24.4 million, a significant increase from approximately $15.03 million in the same period of the previous year.

Portfolio Pulse from Benzinga Newsdesk

December 07, 2023 | 1:35 pm

CHWY

Chewy's stock is trading lower following the release of their mixed Q3 financial results and a reduction in their full-year 2023 net sales forecast.

Portfolio Pulse from Benzinga Newsdesk

December 07, 2023 | 1:27 pm

MAYS

J. W. Mays reported a Q4 2023 EPS of $(0.10), a decrease from $0.03 YoY. Revenue also decreased to $5.323M from $5.769M YoY.

Portfolio Pulse from Benzinga Newsdesk

December 07, 2023 | 1:18 pm

IMMP

Immutep Limited has received a €1.6 million (approximately A$2.6 million) R&D tax incentive payment from the French Government under the Crédit d'Impôt Recherche scheme for eligible R&D activities conducted in the EU during 2022. This follows a previous A$1.13 million cash rebate from the Australian Federal Government for R&D activities in financial year 2022. The funds will support clinical development of eftilagimod alpha and preclinical development of IMP761.

Portfolio Pulse from Benzinga Newsdesk

December 07, 2023 | 1:16 pm

KRRO

Korro Bio, Inc. (KRRO) has nominated KRRO-110, its first RNA editing oligonucleotide candidate from its OPERA platform, for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). KRRO-110 has shown promise in preclinical mouse models, demonstrating the ability to repair the A1AT protein misfolding and reduce liver aggregates. With over 50% editing efficiency and increased secretion of normal A1AT protein, Korro expects to make a regulatory filing in the second half of 2024. AATD is a genetic disorder with limited treatment options, and KRRO-110 could potentially transform the standard of care.

Portfolio Pulse from Benzinga Newsdesk

December 07, 2023 | 1:10 pm

BWAY

BrainsWay has announced that its Deep Transcranial Magnetic Stimulation (Deep TMS) technology will have expanded availability in South Korea. Recent sales are anticipated to increase the company's installed base in South Korea to over 20 systems.

Portfolio Pulse from Benzinga Newsdesk

December 07, 2023 | 1:07 pm

SATL

Uzma has signed a multi-million dollar, three-year agreement with Satellogic (NASDAQ: SATL) to enhance geospatial capabilities in Southeast Asia. The collaboration will leverage an Earth Observation (EO) satellite expected to launch in the second half of 2024, which will advance the region's geospatial data acquisition and analysis.

Portfolio Pulse from Benzinga Newsdesk

December 07, 2023 | 1:06 pm

CDTX

Cidara Therapeutics, Inc. (NASDAQ:CDTX) presented new preclinical data on its novel drug-Fc conjugates at the ESMO Immuno-Oncology Congress. The data showed that its CD73/PD-1 inhibitor DFC and CD73-targeting DFC, CBO421, exhibited robust anti-tumor activity in humanized mouse models of colorectal cancer. The CD73/PD-1 DFC demonstrated superior efficacy compared to monotherapies and is expected to file an IND application in mid-2024 for CBO421.

Portfolio Pulse from Benzinga Newsdesk

December 07, 2023 | 1:05 pm